title: Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol.
abstract: OBJECTIVE
  Here we report the results of a phase III study, to evaluate whether the addition of cisplatin to radiation therapy (XRT) would improve progression-free survival or overall survival for patients with locally advanced unresectable non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Two hundred forty patients with biopsy-proven unresectable NSCLC without distant metastases or lower-stage medically inoperable patients were randomized to one of two treatment arms. Arm A consisted of thoracic XRT alone, 60 to 65 Gy total tumor dose in daily fractions of 1.80 to 2.00 Gy; and arm B consisted of identical XRT with the addition of cisplatin 70 mg/m2 every 3 weeks for three cycles beginning on the first day of irradiation.
  
  
  RESULTS
  Two hundred fifteen patients were eligible and assessable. The overall response rate was 50% on the combination arm versus 38% on the XRT-alone arm (P = .076). The median progression-free survival time was 23 versus 22 weeks, respectively (P = .0537). The median survival time was 43 weeks on the combination arm versus 46 weeks on the XRT arm (Poverall = .3469). The 1-, 2-, and 5-year survival rates were 43%, 18%, and 5% on the combination arm versus 45% 13%, and 2% on the XRT arm, respectively.
  
  
  CONCLUSIONS
  Cisplatin, administered every 3 weeks, does not significantly improve response rate, progression-free survival, or overall survival when added to thoracic XRT for locally advanced unresectable NSCLC.
authors.affiliation: Hoosier Oncology Group, Indiana University, Indianapolis 46208-4687, USA.
authors.forename: C
authors.initials: C
authors.lastname: Blanke
authors.forename: R
authors.initials: R
authors.lastname: Ansari
authors.forename: R
authors.initials: R
authors.lastname: Mantravadi
authors.forename: R
authors.initials: R
authors.lastname: Gonin
authors.forename: R
authors.initials: R
authors.lastname: Tokars
authors.forename: W
authors.initials: W
authors.lastname: Fisher
authors.forename: K
authors.initials: K
authors.lastname: Pennington
authors.forename: T
authors.initials: T
authors.lastname: O'Connor
authors.forename: S
authors.initials: S
authors.lastname: Rynard
authors.forename: M
authors.initials: M
authors.lastname: Miller
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D002423:Cause of Death; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged
chemical_list: D002945:Cisplatin